Candidiasis

• 

  Subject Areas on Research

  • A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. 
  • A meta-analysis of medical versus surgical therapy for Candida endocarditis. 
  • A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. 
  • Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. 
  • Amphotericin B therapy in an anephric patient. 
  • An uncommon gastric finding: a budding problem. 
  • Anastomotic infections in lung transplant recipients. 
  • Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. 
  • Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. 
  • Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients. 
  • Antifungal resistance: the clinical front. 
  • Aquaporin in Candida: characterization of a functional water channel protein. 
  • Autophagy enhances NFκB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity. 
  • Autophagy is redundant for the host defense against systemic Candida albicans infections. 
  • Blood gene expression signatures predict invasive candidiasis. 
  • Breakthrough invasive candidiasis in patients on micafungin. 
  • CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. 
  • Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. 
  • Candida albicans cholecystitis. 
  • Candida albicans corpora abscess following penile prosthesis placement. 
  • Candida bloodstream infection in neonates. 
  • Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD). 
  • Candida fasciitis following renal transplantation. 
  • Candida glabrata endophthalmitis following penetrating keratoplasty. 
  • Candida infective endocarditis. 
  • Candida infective endocarditis: an observational cohort study with a focus on therapy. 
  • Candida mediastinitis after a cardiac operation. 
  • Candida meningitis in two children with severe combined immunodeficiency. 
  • Candida pneumonia in a term infant after prolonged use of inhaled corticosteroids for bronchopulmonary dysplasia (BPD). 
  • Candida virulence properties and adverse clinical outcomes in neonatal candidiasis. 
  • Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. 
  • Candidal mycetoma in the neonatal kidney. 
  • Candidal oesophagitis in Cushing's syndrome. 
  • Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. 
  • Candidal splenic abscesses. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Caspofungin for invasive candidiasis at a tertiary care medical center. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Caspofungin: first approved agent in a new class of antifungals. 
  • Chemotaxis of mononuclear leukocytes. 
  • Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. 
  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 
  • Clinical challenges and images in GI. Invasive candidal enterocolitis. 
  • Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. 
  • Clonal and spontaneous origins of fluconazole resistance in Candida albicans. 
  • Combination antifungals: an update. 
  • Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. 
  • Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. 
  • Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. 
  • Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. 
  • Controlled comparison of BacT/ALERT FAN aerobic medium and BATEC fungal blood culture medium for detection of fungemia. 
  • Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. 
  • Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. 
  • Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? 
  • Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. 
  • Diagnosis of fungal infection: new technologies for the mycology laboratory. 
  • Disseminated Candida tropicalis in a patient with chronic mucocutaneous candidiasis. 
  • Echinocandin pharmacodynamics: review and clinical implications. 
  • Echinocandins: a wealth of choice--how clinically different are they? 
  • Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today. 
  • Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. 
  • Empirical therapy for neonatal candidemia in very low birth weight infants. 
  • Endogenous Candida endophthalmitis: Who is really at risk? 
  • Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. 
  • Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. 
  • Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. 
  • Excess costs of hospital care associated with neonatal candidemia. 
  • External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. 
  • Fatal Henoch-Schonlein purpura in an adult related to bowel perforation: report and review of the literature. 
  • Fatal fungal infection following open-heart surgery. 
  • First, do no harm. 
  • Fluconazole and Candida krusei fungemia. 
  • Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. 
  • Fluconazole loading dose pharmacokinetics and safety in infants. 
  • Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Fungal infection following renal transplantation. 
  • Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. 
  • Fungal mating: Candida albicans flips a switch to get in the mood. 
  • Genetic structure of typical and atypical populations of Candida albicans from Africa. 
  • Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. 
  • Guidelines for treatment of skin diseases in children with HIV infection. 
  • Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia. 
  • High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. 
  • Human dectin-1 deficiency and mucocutaneous fungal infections. 
  • Human genetic susceptibility to Candida infections. 
  • Identification of clinical strains of Candida albicans by DNA fingerprinting with the polymerase chain reaction. 
  • Identification of pathogenic yeasts of the imperfect genus Candida by polymerase chain reaction fingerprinting. 
  • Immunoblot analyses of Candida albicans-associated antigens and antibodies in human sera. 
  • Implant healing in experimental animal models of diabetes. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp. 
  • Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. 
  • Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. 
  • Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. 
  • Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. 
  • Intervertebral diskitis due to Candida tropicalis. 
  • Intramural tracking in esophageal pseudodiverticulosis. 
  • Invasive Candida infections in the neonate. 
  • Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. 
  • Lack of genetic differentiation between two geographically diverse samples of Candida albicans isolated from patients infected with human immunodeficiency virus. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis. 
  • Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. 
  • Mucosal candidiasis elicits NF-κB activation, proinflammatory gene expression and localized neutrophilia in zebrafish. 
  • Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. 
  • Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. 
  • Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. 
  • Mycotic diseases. A proposed nomenclature. 
  • Myeloid-Specific Deletion of Mcl-1 Yields Severely Neutropenic Mice That Survive and Breed in Homozygous Form. 
  • Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. 
  • Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. 
  • Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. 
  • Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. 
  • Neonatal candidiasis. 
  • Neonatal candidiasis: diagnosis, prevention, and treatment. 
  • Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. 
  • Neonatal candidiasis: prophylaxis and treatment. 
  • Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. 
  • Next-generation computational genetic analysis: multiple complement alleles control survival after Candida albicans infection. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Opportunistic fungal pneumonia. 
  • Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Outcomes following candiduria in extremely low birth weight infants. 
  • PCR-restriction fragment length polymorphism (RFLP) analyses reveal both extensive clonality and local genetic differences in Candida albicans. 
  • Pathogenesis of fungal infection on heart valve prosthesis. 
  • Pathologic quiz case 2. Disseminated candidiasis with secondary involvement in the larynx. 
  • Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. 
  • Persistence of the same Candida albicans strain despite fluconazole therapy. Documentation by pulsed-field gel electrophoresis. 
  • Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Pharmacokinetics of an elevated dosage of micafungin in premature neonates. 
  • Pharmacological resolution of a multiloculated Candida spp. liver abscess in a preterm neonate. 
  • Phosphate-containing polyethylene glycol polymers prevent lethal sepsis by multidrug-resistant pathogens. 
  • Phylogeny and evolution of medical species of Candida and related taxa: a multigenic analysis. 
  • Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO. 
  • Population pharmacokinetics of fluconazole in young infants. 
  • Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. 
  • Population pharmacokinetics of micafungin in neonates and young infants. 
  • Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Potential Microbiological Effects of Higher Dosing of Echinocandins. 
  • Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. 
  • Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. 
  • Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. 
  • Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. 
  • Prevention and treatment of nosocomial sepsis in the NICU. 
  • Prophylaxis of invasive mycoses in solid organ transplantation. 
  • Pseudophakic Candida parapsilosis endophthalmitis with a consecutive keratitis. 
  • Purulent pericarditis caused by Candida: report of three cases and identification of high-risk populations as an aid to early diagnosis. 
  • Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. 
  • Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. 
  • Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. 
  • Recovery from disseminated candidiasis in a premature neonate. 
  • Reduced Visual Acuity Following Kidney Stone Extraction. 
  • Renal candidiasis in neonates with candiduria. 
  • Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. 
  • Retinal manifestations of the acquired immune deficiency syndrome (AIDS): cytomegalovirus, candida albicans, cryptococcus, toxoplasmosis and Pneumocystis carinii. 
  • Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. 
  • Role of autophagy genetic variants for the risk of Candida infections. 
  • Safety and pharmacokinetics of repeat-dose micafungin in young infants. 
  • Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. 
  • Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. 
  • Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation. 
  • Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin. 
  • Species and genotypic diversities and similarities of pathogenic yeasts colonizing women. 
  • Successfully treated postoperative Candida parakrusei endophthalmitis. 
  • Synthesis and antifungal activities of miltefosine analogs. 
  • Systemic Torulopsis glabrata infection in a neonate. 
  • The Ubiquitin-Modifying Enzyme A20 Terminates C-Type Lectin Receptor Signals and Is a Suppressor of Host Defense against Systemic Fungal Infection. 
  • The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. 
  • The incidence and management of pulmonary mycosis in renal allograft patients. 
  • The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. 
  • The retinal lesions of the acquired immune deficiency syndrome. 
  • The use of antifungal therapy in neonatal intensive care. 
  • Torulopsis glabrata fungemia--a clinical pathological study. 
  • Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. 
  • Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. 
  • Treatment of experimental disseminated candidiasis with cilofungin. 
  • Treatment of neonatal fungal infections. 
  • Tricuspid valve Candida endocarditis. Successful treatment with valve-sparing debridement and antifungal chemotherapy in a multiorgan transplant recipient. 
  • Unusual cause of superior vena cava syndrome diagnosed with transesophageal echocardiography. 
  • Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. 
  • Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. 
  • Use of fluconazole in a patient with documented malabsorption of ketoconazole. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. 
  • Vertebral Candida infections. A case report and review of the literature. 
  • Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis. 
  • Voriconazole treatment for less-common, emerging, or refractory fungal infections. 
  • When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor of Pediatrics, in the School of Medicine, Immunology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Cunningham, Coleen Kathryn, Adjunct Professor in the Department of Pediatrics, Pediatrics
  • Steinbach, William J., Samuel L. Katz Distinguished Professor of Pediatrics, Molecular Genetics and Microbiology